Live
BioPharma DiveFDA hold puts Aardvark Prader-Willi drug in limboBioPharma DiveSupreme Court preserves access to abortion pill by mailBioPharma DiveBiotech leaders campaign for Pazdur; Takeda to lay off 4,500 workersEndpoints NewsCandel reports prostate cancer drug's long-term data ahead of FDA filingEndpoints NewsPost-Hoc Live: Makary's out at FDA and what comes nextCellThe immunoproteasome disturbs neuronal metabolism and drives neurodegeneration in multiple sclerosisFierceBiotechNovartis, amid reorg, cuts ‘select number’ of biomedical research rolesPharmaVoiceSanofi’s vaccine bump; the new FDA commishEndpoints NewsAardvark's next move after clinical hold; Alumis' verdict on Acelyrin assetFierceBiotechWhy Model Medicines needs to ‘discover new colors’ in its AI drug discovery questBioPharma DiveIndia’s pharma industry is going global. But can it catch up to China?BioWorldSanofi identifies YAP1/TEAD and TAZ/TEAD interaction inhibitors
Cell Mar 31, 2026

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy

Original
Body unavailable. Use the original source.